## Appendix E. Final Documents [Case-Based] osacea

Systematic Review of Treatments

Source: van Zuuren EJ, Gupta AK, Grover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J Am Acad Dermatol. 2007 Jan;56(1): 107 - 15

Conflicts of Interest: None identified to the journal citation

## **CLINICAL SUMMARY**

#### EFFECTIVE

••• Topical metronidazole and azelaic acid are effective for short-term use.

• OO There is some evidence that oral tetracycline may be effective for ocular rosacea.

#### UNKNOWN EFFECT

- · There is insufficient RCT evidence to assess rilmenidine (for flushing), benzoyl peroxide/clindamycin (for limited pustules), or sulfacetamide/ sulfur (for limited pustules).
- There is no RCT evidence available on clonidine (for flushing), tretinoin cream (for limited pustules), ampicillin (for extensive skin lesions), isotretinoin (for persistent rosacea), metrondizole (for ocular rosacea), or fusidic acid gel (for ocular rosacea).
- There is no RCT evidence available on any treatments for vascular symptoms or rhinophyma.

## UNLIKELY EFFECTIVE

· Nothing to report.

#### POSSIBLY INNEFFECTIVE OR HARMFUL

· Nothing to report.

#### **REVIEW INFORMATION**

Participants	Adults, 19 years or older with moderate to severe rosacea
Interventions	Any type of rosacea treatment
Outcomes	Participant-assessed changes in rosacea severity and impact on quality of life
Study Types	Randomized controlled trials
Limitations	Quality of the studies was generally poor

#### ODDS RATIOS (OR)

Compares if the odds of an event is the same for two groups

OR=1 The event is equally likely in both groups.

OR>1 The event is more likely in the exposed group.

Case-Based ] CLINICAL CONDITION		TREATMENTS	# weeks follow-up in trial participants	# trials	OUTCOMES	ADVERSE EVENTS
Limited Number of Papules / Pustules	Analysis	Topical metronidazole (0.75% and 1%) Participants: 68 (topical metronidazole), 32 (placebo)	8–9	2	●●○ Favours topical metronidazole OR: 5.96; 95% Cl: 2.96–12.06	Mild: including pruritis, skin irritation, dry skin
	Meta-	Topical azelaic acid (15% gel, 20% cream) Participants: 260 (azelaic cream), 149 (placebo)	9–12	3	●●○ Favours topical azelaic acid OR 2.45; 95% CI: 1.82–3.28	Mild and transient: burning, stinging, irritation
		Benzoyl peroxide 5% / clindamycin 1% gel	12	1	Significantly superior to placebo ( <i>p</i> = .0002)	Site burning and itching
		Sodium sulfacetamide 10% / sulfur 5%	n/a	1	Significantly superior to placebo ( <i>p</i> < .001)	Dryness, erythema, pruritis
		Topical permethrin v. Topical metronidazole	n/a	1	Inferior to topical metronidazole	Not addressed in study
		Topical azelaic acid v. Topical metronidazole	15	2	No statistical significant difference in efficacy between topical metronidazole and topical azelaic acid	Mild to moderate, mostly transient: burning, stinging, irritation
		Metronidazole plus sunscreen SPF 15	n/a	1	Poorly designed study favoured metronidazole plus sun-screen over placebo	Not addressed in study
More Extensive Skin Lesions		Tetracycline	4–6	3	Oral tetracycline is more effective than placebo by physician assessment (OR: 6.06; 95% CI: 2.96–12.42) but not by patient assessment	Not addressed in study
		Oral metronidazole v. Oral oxytetracycline	12	1	No statistically significant difference between the two	Not addressed in study
		Oral tetracycline v. Topical metronidazole	8	2	therapies	
		Benzoyl peroxide 5% / erythromycin 3% gel and metronidazole	4	1		
		Clarithromycin and omeprazole	n/a	1	Impossible to draw conclusions from data	Not addressed in study
Flushing		Rilmenidine	n/a	1	Rilmenidine not significantly better than placebo	Not addressed in study
Eye Irritation (Ocular Rosacea)		Tetracycline (250 mg b.d. for 6 weeks)	6	1	Oral oxytetracycline may be more effective for ocular rosacea by physician assessment	Not addressed in study

## NO RANDOMIZED CONTROLLED TRIALS **AVAILABLE FOR EVALUATION**

CLINICAL CONDITION	TREATMENTS			
Limited Number of Papules / Pustules	Tretinoin			
More Extensive Skin Lesions	Ampicillin			
Flushing	Clonidine			
Vascular Rosacea	Pulse dye laser, intense pulsed light			
Severe or Persistent Rosacea	Isotretinoin			
Eye Irritation (Ocular Rosacea)	Metrondiazole; Fusidic acid gel			
Rhinophyma	Isotretinoin (low-dose); Laser therapy; Surgical Interventions			

<b>STRENGTH OF RESEARCH EVIDENCE</b> Ratings are based on the overall quantity and quality of clinical evidence.		
STRONG	Results consistent from high quality studies. Conclusions unlikely to change with further research.	
••• MODERATE	Current research supports findings, however conclusions could change with further research.	
• O O WEAK	Limited studies available for drawing conclusions, or existing studies have significant limitations.	



#### Systematic Review of Treatments

**Source:** van Zuuren EJ, Gupta AK, Grover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J Am Acad Dermatol. 2007 Jan;56(1): 107–15

**Conflicts of Interest:** None identified to the journal citation

#### SYSTEMATIC REVIEW ABSTRACT

#### Purpose

To assess the evidence for the efficacy and safety of rosacea therapies.

#### Methods

- Medline, EMBASE, the Cochrane Library, BIOSIS, and the Science Citation Index were systematically searched.
- Study selection, assessment of methodologic quality, data extraction, and analysis were carried out by two independent researchers.

#### Results

- 29 studies met the inclusion criteria.
- Topical metronidazole is more effective than placebo (odds ratio 5.96, 95% confidence interval 2.95–12.06).
- Azelaic acid is more effective than placebo (odds ratio 2.45, 95% confidence internal 1.82– 3.28).
- Firm conclusions could not be drawn about other pharmacological and nonpharmacological therapies.

## **APPLYING THE EVIDENCE**

#### Example

- A 35-year old woman had developed moderate swelling, erythma and papules of the central part of her face for 8 weeks.
- She had been applying various topical cosmetic products sold for acne withno change in her condition.
- One of her hobbies is hiking and she noticed sun exposure aggravated her skin condition, also resulting in burning and stinging sensations.

#### Treatment

 The patient consulted her family physician who prescirbed topical treatment with metronidazole 1% and oral treatment with metronidazole 500 mg twice daily for two weeks.

#### **Outcome & Follow-up**

- After an initial worsening during the first 3 days the skin condition improved.
- The topical treatment was continued twice daily for 4 weeks and then reduced to once daily for an additional 4 weeks. As well, sun screen was applied whenever outdoors.

The case study used in Applying the Evidence is adapted from: rosacea.dermis.net/content/ e05quizcase/index\_eng.html. Used with permission.



© DermAtlas; www.DermAtlas.org. Used with permission.

[Evidence-Expertise]

Systematic Review of Treatments Source: van Zuuren EJ, Gupta AK, Grover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J Am Acad Dermatol. 2007 Jan;56(1):

107–15 Conflicts of Interest: None identified to the

journal citation

## **EXPERT INTERPRETATION**

- Topical metronidazole cream (0.75% and 1%) and azelaic acid cream (15 and 20%) are effective and safe for short term use (8–12 weeks).
- Oral oxytetracycline (250mg oxytetracycline dihydrate [Clinimycin] one capsule twice daily) may be effective for ocular rosacea.
- Oral tetracycline is more effective than placebo for physician assessment but not for patient outcomes.
- There is no evidence for use of other agents including dapsone, erythromycin, topical tretinoin, benzoyl peroxide, diet or sun protection.
- The quality of reported studies is poor with lack of blinding, allocation concealment, and intention to treat analysis.

2

Sharon E. Straus, MD University of Toronto, Toronto Canada **Conflict of Interest:** None identified

## **REVIEW INFORMATION**

Participants	Adults, 19 years or older with moderate to severe rosacea
Interventions	Any type of rosacea treatment
Outcomes	Participant-assessed changes in rosacea severity and impact on quality of life
Study Types	Randomized controlled trials
Synopsis	29 RCTs were included, 8 were classified as high quality
	Topical metronidazole is more effective than placebo (OR 5.96; 95% confidence interval 2.95–12.06)
	Topical azelaic acid is more effective than placebo (OR 2.45; 95% confidence interval 1.82–3.28)
	Firm conclusions could not be drawn about other therapies
ODDS RATIO	S (OR)

Compares if the odds of an event is the same for two groups

```
OR=1
The event is equally likely in both groups.

OR>1
The event is more likely in the
```

exposed group.

CLINICAL CONDITION	TREATMENTS	# weeks follow-up in trial participants	# trials	OUTCOMES	ADVERSE EVENTS
Limited Number of Papules / Pustules Weta-Pually sis	Topical metronidazol (0.75% and 1%) Participants: 68 (topic metronidazole), 32 (placebo)		2	●●○ Favours topical metronidazole OR: 5.96; 95% CI: 2.96–12.06	Mild: including pruritis, skin irritation, dry skin
	Topical azelaic acid (2) gel, 20% cream) Participants: 260 (aze cream), 149 (placebo)	elaic	3	●●○ Favours topical azelaic acid OR 2.45; 95% CI: 1.82–3.28	Mild and transient: burning, stinging, irritation
	Benzoyl peroxide 5% clindamycin 1% gel	/ 12	1	Significantly superior to placebo ( <i>p</i> = .0002)	Site burning and itching
	Sodium sulfacetamid 10% / sulfur 5%	le n/a	1	Significantly superior to placebo (p < .001)	Dryness, erythema, pruritis
	Topical permethrin v. Topical metronidazol		1	Inferior to topical metronidazole	Not addressed in study
	Topical azelaic acid v Topical metronidazol		2	No statistical significant difference in efficacy between topical metronidazole and topical azelaic acid	Mild to moderate, mostly transient: burning, stinging, irritation
	Metronidazole plus sunscreen SPF 15	n/a	1	Poorly designed study favoured metronidazole plus sun-screen over placebo	Not addressed in study
More Extensive Skin Lesions	Tetracycline	4-6	3	Oral tetracycline is more effective than placebo by physician assessment (OR: 6.06; 95% CI: 2.96–12.42) but not by patient assessment	Not addressed in study
	Oral metronidazole v Oral oxytetracycline	. 12	1	No statistically significant difference between the two	Not addressed in study
	Oral tetracycline v. Topical metronidazol	le 8	2	therapies	
	Benzoyl peroxide 5% erythromycin 3% gel metronidazole		1		
	Clarithromycin and omeprazole	n/a	1	Impossible to draw conclusions from data	Not addressed in study
Flushing	Rilmenidine	n/a	1	Rilmenidine not significantly better than placebo	Not addressed in study
Eye Irritation (Ocular Rosacea)	Tetracycline (250 mg for 6 weeks)	b.d. 6	1	Oral oxytetracycline may be more effective for ocular rosacea by physician assessment	Not addressed in study

# NO RANDOMIZED CONTROLLED TRIALS AVAILABLE FOR EVALUATION

CLINICAL CONDITION	TREATMENTS			
Limited Number of Papules / Pustules	Tretinoin			
More Extensive Skin Lesions	Ampicillin			
Flushing	Clonidine			
Vascular Rosacea	Pulse dye laser, intense pulsed light			
Severe or Persistent Rosacea	Isotretinoin			
Eye Irritation (Ocular Rosacea)	Metrondiazole; Fusidic acid gel			
Rhinophyma	Isotretinoin (low-dose); Laser therapy; Surgical Interventions			

<b>STRENGTH OF RESEARCH EVIDENCE</b> Ratings are based on the overall quantity and quality of clinical evidence.			
STRONG	Results consistent from high quality studies. Conclusions unlikely to change with further research.		
••O MODERATE	Current research supports findings, however conclusions could change with further research.		
• O O WEAK	Limited studies available for drawing conclusions, or existing studies have significant limitations.		